Alopecia Areata Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Market Overview:

The top 7 (US, EU4, UK, and Japan) alopecia areata markets are expected to exhibit a CAGR of 6.24% during 2025-2035.

The alopecia areata market has been comprehensively analyzed in IMARC's new report titled "Alopecia Areata Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Alopecia areata refers to a common autoimmune disorder that leads to hair loss on the scalp and other areas of the body. It usually occurs when the immune system mistakenly attacks hair follicles, which leads to tissue scarring and hair loss. The appearance of small, coin-sized, round patches on the scalp characterizes this condition. Symptoms associated with the ailment include hair loss, itching, anxiety, exclamation point hairs, small dents in nails, etc. The diagnosis of alopecia areata is typically made by analysis of the patient’s clinical features, medical history, and physical exam. Trichoscopy, which is a quick, non-invasive, and easy-to-perform procedure that helps to detect subtle details and validate a correct diagnosis, is also adopted by several healthcare professionals. Various other diagnostic studies include blood workups, antinuclear antibody tests, C-reactive protein tests, biopsy, etc., to rule out other possible causes of underlying symptoms among patients.

To get more information on this market, Request Sample

The rising cases of autoimmune disorders in which the white blood cells attack hair follicles, resulting in their shrinkage and damage, are primarily driving the alopecia areata market. Additionally, the increasing prevalence of several associated risk factors, including genetic predisposition, injury, poor nutrition, comorbidities, severe emotional stress, etc., is also augmenting the market growth. Furthermore, the widespread adoption of immunosuppressant drugs, including methotrexate, cyclosporine, azathioprine, etc., which work by blocking the immune response that causes hair loss, is creating a positive outlook for the market. Apart from this, the inflating utilization of phototherapy for stimulating hair growth in patients and minimizing inflammation and itching is acting as another significant growth-inducing factor. Additionally, the escalating demand for hair implants that involve transplanting follicular grafts to the affected area in order to restore hair follicles and treat receding hairlines or spots of baldness is also bolstering the market growth. Moreover, the ongoing advancements in micro-needling techniques, since they stimulate neovascularization, hair bulge and the release of growth factors, are expected to drive the alopecia areata market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the alopecia areata market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for alopecia areata and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the alopecia areata market in any manner.

Recent Developments:

• In October 2024, Sun Pharmaceutical Industries Limited released new data highlighting the clinical efficacy and safety of LEQSELVI (deuruxolitinib) 8 mg tablets. The results stated that 32.6% of patients receiving LEQSELVI 8 mg BID (twice daily) achieved a SALT ≤20 score; the percentage of SALT 20 responders increased to 48.8% (LOCF analysis) and 76.6% (AO analysis) at Week 68 of the OLE studies. Additionally, 99.6% (282 patients) maintained their response to LEQSELVI 8 mg BID. The U.S. FDA approved LEQSELVI 8 mg tablets for the treatment of adults with severe alopecia areata.
• In June 2023, Pfizer Inc. stated that the United States FDA had approved LITFULO (ritlecitinib), a once-daily oral therapy for people aged 12 and above with severe alopecia areata. The approved recommended dose of LITFULO is 50 mg. It is the first and only FDA-approved medication for adolescents (12 and older) with severe alopecia areata.
• In June 2023, Legacy Healthcare announced that its Marketing Authorization Application (MAA) for Coacillium for the management of moderate to severe alopecia areata in children and adolescents has been validated and is now being reviewed by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).

Drugs:

Olumiant (baricitinib) treats alopecia areata by inhibiting Janus kinase (JAK) enzymes, specifically JAK1 and JAK2. These enzymes are involved in the JAK-STAT signaling pathway, which plays a crucial role in the immune system and inflammation. By blocking JAK activity, Olumiant reduces the production of inflammatory cytokines, thereby preventing the immune system from attacking hair follicles and promoting hair regrowth.

PF-06651600 is an oral small molecule that specifically inhibits Janus kinase (JAK) 3 for the management of alopecia areata. The JAK pathways are considered to play a key role in inflammatory processes because they signal for more than 50 cytokines and growth factors, many of which cause immune-mediated diseases.

Coacillium (LH-8) from Legacy Healthcare, a botanical drug candidate for alopecia areata, works through a pleiotropic mechanism. It primarily focuses on reversing immuno-inflammatory reactions in hair follicles and promoting hair regrowth. The drug contains flavonoids, polyphenols, and methylxanthines, which are believed to modulate the immune response and protect hair follicles from damage.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the alopecia areata market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the alopecia areata market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current alopecia areata marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the alopecia areata market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the alopecia areata across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the alopecia areata across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of alopecia areata across the seven major markets?
• What is the number of prevalent cases (2019-2035) of alopecia areata by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of alopecia areata by gender across the seven major markets?
• What is the number of prevalent cases (2019-2035) of alopecia areata by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with alopecia areata across the seven major markets?
• What is the size of the alopecia areata patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend alopecia areata of?
• What will be the growth rate of patients across the seven major markets?

Alopecia Areata: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for alopecia areata drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the alopecia areata market?
• What are the key regulatory events related to the alopecia areata market?
• What is the structure of clinical trial landscape by status related to the alopecia areata market?
• What is the structure of clinical trial landscape by phase related to the alopecia areata market?
• What is the structure of clinical trial landscape by route of administration related to the alopecia areata market?